Daiichi Sankyo Inc Drug Patent Portfolio

Daiichi Sankyo Inc's Family Patents

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List

Daiichi Sankyo of Japan plans to expand its production facilities in China and the United States due to potential tariff concerns - Nikkei Asia

02 Jan, 2026

AZN and Daiichi's Enhertu Receives Breakthrough Designation for Broader Cancer Application - TradingView

22 Dec, 2025

Lunit collaborates with Daiichi Sankyo to enhance the development of innovative cancer treatments through artificial intelligence.

16 Dec, 2025

AZN and Daiichi's Enhertu Approved by FDA for Initial Treatment of Breast Cancer - Finviz

16 Dec, 2025